Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219284 · ClinicalTrials.gov registry record · Phase 4
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 359
- Enrollment target
NCT00219284: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT00219284 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 359 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219284, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 359 participants
- Enrollment target
Study Summary
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
Primary Outcome
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
Interventions
- DRUG Carbidopa/levodopa/entacapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00219284 record still lists
NCT00219284 is an interventional study that assigns participants to a tested intervention. The registered 359 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which Carbidopa/levodopa/entacapone is the first listed.
NCT00219284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219284 about?
NCT00219284 is a clinical study titled "Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease". To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
What is the current status of trial NCT00219284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 359 participants. The study started on 2005-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00219284?
The interventions under investigation include: Carbidopa/levodopa/entacapone (DRUG).
Who is sponsoring clinical trial NCT00219284?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00219284's enrollment target sits among peer trials
359 226th of 2000 higher than 1,775 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05118789 · 359 participants · Phase 1
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia